Maternal, Infant, and Breast Milk Antibody Response Following COVID-19 Infection in Early Versus Late Gestation
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved..
BACKGROUND: Coronavirus disease 2019 [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] infection at varying time points during the pregnancy can influence antibody levels after delivery. We aimed to examine SARS-CoV-2 IgG, IgM and IgA receptor binding domain of the spike protein and nucleocapsid protein (N-protein) reactive antibody concentrations in maternal blood, infant blood and breastmilk at birth and 6 weeks after SARS-CoV-2 infection in early versus late gestation.
METHODS: Mothers with SARS-CoV-2 infection during pregnancy were enrolled between July 2020 and May 2021. Maternal blood, infant blood and breast milk samples were collected at delivery and 6 weeks postpartum. Samples were analyzed for SARS-CoV-2 spike and N-protein reactive IgG, IgM and IgA antibodies. Antibody concentrations were compared at the 2 time points and based on trimester of infection ("early" 1st/2nd vs. "late" 3rd).
RESULTS: Dyads from 20 early and 11 late trimester infections were analyzed. For the entire cohort, there were no significant differences in antibody levels at delivery versus 6 weeks with the exception of breast milk levels which declined over time. Early gestation infections were associated with higher levels of breastmilk IgA to spike protein ( P = 0.04). Infant IgG levels to spike protein were higher at 6 weeks after late infections ( P = 0.04). There were strong correlations between maternal and infant IgG levels at delivery ( P < 0.01), and between breastmilk and infant IgG levels.
CONCLUSIONS: SARS-CoV-2 infection in early versus late gestation leads to a persistent antibody response in maternal blood, infant blood and breast milk over the first 6 weeks after delivery.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
The Pediatric infectious disease journal - 42(2023), 3 vom: 01. März, Seite e70-e76 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wachman, Elisha M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 24.02.2023 Date Revised 12.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/INF.0000000000003802 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352400188 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352400188 | ||
| 003 | DE-627 | ||
| 005 | 20231226053635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/INF.0000000000003802 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352400188 | ||
| 035 | |a (NLM)36729773 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wachman, Elisha M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Maternal, Infant, and Breast Milk Antibody Response Following COVID-19 Infection in Early Versus Late Gestation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2023 | ||
| 500 | |a Date Revised 12.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Coronavirus disease 2019 [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] infection at varying time points during the pregnancy can influence antibody levels after delivery. We aimed to examine SARS-CoV-2 IgG, IgM and IgA receptor binding domain of the spike protein and nucleocapsid protein (N-protein) reactive antibody concentrations in maternal blood, infant blood and breastmilk at birth and 6 weeks after SARS-CoV-2 infection in early versus late gestation | ||
| 520 | |a METHODS: Mothers with SARS-CoV-2 infection during pregnancy were enrolled between July 2020 and May 2021. Maternal blood, infant blood and breast milk samples were collected at delivery and 6 weeks postpartum. Samples were analyzed for SARS-CoV-2 spike and N-protein reactive IgG, IgM and IgA antibodies. Antibody concentrations were compared at the 2 time points and based on trimester of infection ("early" 1st/2nd vs. "late" 3rd) | ||
| 520 | |a RESULTS: Dyads from 20 early and 11 late trimester infections were analyzed. For the entire cohort, there were no significant differences in antibody levels at delivery versus 6 weeks with the exception of breast milk levels which declined over time. Early gestation infections were associated with higher levels of breastmilk IgA to spike protein ( P = 0.04). Infant IgG levels to spike protein were higher at 6 weeks after late infections ( P = 0.04). There were strong correlations between maternal and infant IgG levels at delivery ( P < 0.01), and between breastmilk and infant IgG levels | ||
| 520 | |a CONCLUSIONS: SARS-CoV-2 infection in early versus late gestation leads to a persistent antibody response in maternal blood, infant blood and breast milk over the first 6 weeks after delivery | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Snyder-Cappione, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Devera, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Boateng, Jeffery |e verfasserin |4 aut | |
| 700 | 1 | |a Dhole, Yashoda |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Yuen, Rachel R |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Samantha E |e verfasserin |4 aut | |
| 700 | 1 | |a Hunnewell, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Ferraro, Renee |e verfasserin |4 aut | |
| 700 | 1 | |a Jean-Sicard, Sigride |e verfasserin |4 aut | |
| 700 | 1 | |a Woodard, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Cruikshank, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Bharati |e verfasserin |4 aut | |
| 700 | 1 | |a Bartolome, Ruby |e verfasserin |4 aut | |
| 700 | 1 | |a Barnett, Elizabeth D |e verfasserin |4 aut | |
| 700 | 1 | |a Yarrington, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Taglauer, Elizabeth S |e verfasserin |4 aut | |
| 700 | 1 | |a Sabharwal, Vishakha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Pediatric infectious disease journal |d 1991 |g 42(2023), 3 vom: 01. März, Seite e70-e76 |w (DE-627)NLM012615706 |x 1532-0987 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:3 |g day:01 |g month:03 |g pages:e70-e76 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/INF.0000000000003802 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 3 |b 01 |c 03 |h e70-e76 | ||